Intimation of Analyst/Investor Meet

Beta Drugs Limited

Event Type: Q4 FY26 Earnings Conference Call hosted by PhillipCapital PCG

Date and Time: May 15, 2026 (time not specified)

Purpose: Discussion of Q4 and full year FY26 financial results, business performance across segments, and strategic updates including the Nivian Lifesciences acquisition and Vision 2030.

Management Participants:

  • Mr. Rahul Batra – Chairman and Managing Director
  • Mr. Nipun Arora – Chief Financial Officer
  • Mr. Ashutosh Shukla – Director, Sales & Marketing
  • Ms. Rajni Brar – Company Secretary

Moderator: Mr. Srisurya K from PhillipCapital PCG Desk

Financial Period Discussed: Q4 FY26 and Full Year FY26 (April 2025-March 2026)

Key Financial Highlights (FY26 vs FY25):

  • Net revenue: INR396 crores (up from INR368 crores)
  • Gross margin: 55.52% (up from 52.71%)
  • EBITDA: INR86.85 crores (up from INR76.97 crores)
  • EBITDA margin: 22.57% (up from 21.1%)
  • Operating margin: 18.11% (up from 17.65%)
  • Net profit margin: 10.78% (down from 11.71%)
  • Other income: INR11 crores (INR8.5-9 crores from FDR interest, INR2-2.5 crores from duty drawback/MEIS)

Segment-wise Performance (FY26):

  • Branded sales: INR123 crores (20% growth)
  • CDMO sales: INR149 crores (1% growth)
  • Export sales: INR71 crores (11% decline)
  • Derma sales: INR16.58 crores (35% growth)
  • API business: INR25 crores (23% growth)

Strategic Developments:

  • Acquired 66.1% stake in Nivian Lifesciences for INR69.4 crore at INR105 crore valuation (closed April 2026)
  • Nivian FY26 revenue: INR45-46 crores with EBITDA margins of 18-19% and PAT of 9-10%
  • Derma business became EBITDA positive in last 6 months
  • API plant cleared PIC/S audit
  • Submitted 3 dossiers for EU audit scheduled September 2026
  • Submitted over 200 dossiers in past 1.5 years, expecting ~100 new registrations

Segment-wise EBITDA Margins (FY26):

  • Branded sales: 35-36%
  • CDMO: 17-18%
  • Exports: 20-21%
  • API: 21%
  • Derma: Gross margin 57-58%

Forward-looking Statements:

  • Vision 2030: Target to achieve INR900+ crore revenue by FY30
  • FY27 export growth guidance: 50%+ (from INR71 crore base)
  • Annual growth target: 20-25% across business verticals
  • Export contribution target: 30% of total revenue by FY30
  • Derma division growth target: 30-40% annually
  • Nivian growth target: 30% for next 3-4 years
  • Planned launches: 20-25 new products in next 3-4 years including NDDS

Capacity Utilization:

  • Oral: 40-45% utilization (55% idle capacity)
  • Injectable liquid: 60-65% utilization (35-40% idle capacity)
  • Lyophilization (Lyo): 85% utilization (planning to install 2 more Lyo machines)

Capital Expenditure:

  • KSM plant total cost: INR27 crores (including land, machinery)

Compliance Statement: The transcript does not contain any specific statement regarding unpublished price sensitive information (UPSI).

Additional Notes Section

The document is a complete transcript of the earnings conference call containing detailed financial performance, segment analysis, and forward-looking guidance. No attachments were mentioned in the transcript. The call included substantial financial data and operational metrics across all business segments.